Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes | Zendy

George L. Bakris | Zendy; Rajiv Agarwal | Zendy; Stefan D. Anker | Zendy; Bertram Pitt | Zendy; Luís M. Ruilope | Zendy; Peter Rossing | Zendy; Peter Kolkhof | Zendy; Christiowack | Zendy; Patrick Schloemer | Zendy; Amer Joseph | Zendy; Jingmei Li | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Author(s) -

George L. Bakris,

Rajiv Agarwal,

Stefan D. Anker,

Bertram Pitt,

Luís M. Ruilope,

Peter Rossing,

Peter Kolkhof,

Christiowack,

Patrick Schloemer,

Amer Joseph,

Jingmei Li

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2025845

Subject(s) - medicine , albuminuria , kidney disease , renal function , creatinine , diabetes mellitus , type 2 diabetes , myocardial infarction , hazard ratio , urology , endocrinology , confidence interval

Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research